Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Faron Pharmaceuticals

Drug Profile

Interferon beta-1a - Faron Pharmaceuticals

Alternative Names: FP-1201; FP-1201-lyo; MR11A8; Recombinant human interferon beta-1a - Faron Pharmaceuticals; Traumakine

Latest Information Update: 25 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Faron Pharmaceuticals
  • Developer Faron Pharmaceuticals; Maruishi Pharmaceutical
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta-1a replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome; Acute lung injury
  • New Molecular Entity No
  • Available For Licensing Yes - Adult respiratory distress syndrome

Highest Development Phases

  • Phase III Adult respiratory distress syndrome
  • Phase II Acute lung injury
  • Discontinued Abdominal aortic aneurysm; Brain injuries; Spinal cord injuries

Most Recent Events

  • 18 Aug 2020 Faron Pharmaceuticals plans a phase II/III HIBISCUS trial for Adult respiratory distress syndrome in USA (IV)
  • 30 May 2020 Faron pharmaceuticals plans a clinical trial for Acute Respiratory distress syndrome without concomitant use of glucocorticoids
  • 27 Apr 2020 World Health Organisation (WHO) plans a clinical trial for COVID-2019 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top